These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G. Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828 [Abstract] [Full Text] [Related]
4. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. Czajka H, Unal S, Ulusoy S, Usluer G, Strus A, Sennaroglu E, Guzik J, Topeli Iskit A, Dargiewicz A, Musial D, Caylan R, Dziduch J, Eskioglu E, Hasiec B, Cwinarowiczliwa E, Belli R, Abdel-Messih IA, Beygo J, Fragapane E. J Prev Med Hyg; 2012 Sep 08; 53(3):136-42. PubMed ID: 23362618 [Abstract] [Full Text] [Related]
9. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. J Infect Dis; 2008 Mar 01; 197(5):667-75. PubMed ID: 18260764 [Abstract] [Full Text] [Related]
11. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R. J Infect Dis; 2011 Jun 15; 203(12):1719-28. PubMed ID: 21606530 [Abstract] [Full Text] [Related]
12. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M. Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791 [Abstract] [Full Text] [Related]
14. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G. Vaccine; 2012 Jul 06; 30(32):4820-7. PubMed ID: 22626675 [Abstract] [Full Text] [Related]
17. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P. Pediatr Infect Dis J; 2010 Jun 06; 29(6):e35-46. PubMed ID: 20375709 [Abstract] [Full Text] [Related]